Clinical Trials · NCT06982859
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
- Phase
- Phase 1
- Recruitment status
- Recruiting
- Sponsor
- Eli Lilly and Company
- Enrollment
- 95
- Start date
- Jun 2025
- Locations
- 1 site, Germany
- Primary endpoint
- Change from Baseline in Total Clamp Disposition Index (cDI) for Comparison of Retatrutide With Placebo